Overview
Study to Evaluate the Safety and PK of UI018
Status:
Recruiting
Recruiting
Trial end date:
2022-09-05
2022-09-05
Target enrollment:
0
0
Participant gender:
All
All
Summary
This Study is to evaluate the safety and pharmacokinetics of a fixed dose combination formulation and co-administration.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Korea United Pharm. Inc.
Criteria
Inclusion Criteria:- Healthy subjects between the ages of 19 and 45 years at screening
- Subjects whose body weight over 55 kg and ranged ± 20% of calculated Ideal body
Weight(IBW) [ IBW (kg) = (height(cm) - 100) x 0.9 ]
- Subjects able to read and understand a written informed consent, and willing to decide
to participate in the study.